Evidence map›Paper›PMID 28542326›Full record

ArticlePLoS pathogens2017

The murine cytomegalovirus M35 protein antagonizes type I IFN induction downstream of pattern recognition receptors by targeting NF-κB mediated transcription.

Baca Chan, Vladimir Gonçalves Magalhães, Niels A W Lemmermann, Vanda Juranić Lisnić, Markus Stempel, Kendra A Bussey, Elisa Reimer, Jürgen Podlech, Stefan Lienenklaus, Matthias J Reddehase and 2 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Regulation of cGAS-Mediated Immune Responses and Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020
    Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Baca ChanViral Immune Modulation Research Group, Helmholtz Centre for Infection Research (HZI), Braunschweig, Germany.ORCID http://orcid.org/0000-0003-0788-9503
Vladimir Gonçalves MagalhãesViral Immune Modulation Research Group, Helmholtz Centre for Infection Research (HZI), Braunschweig, Germany.ORCID http://orcid.org/0000-0002-4593-3467
Niels A W LemmermannInstitute for Virology and Research Center for Immunotherapy (FZI), University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.ORCID http://orcid.org/0000-0001-9190-6497
Vanda Juranić LisnićCenter for Proteomics, Faculty of Medicine, University of Rijeka, Rijeka, Croatia.ORCID http://orcid.org/0000-0002-7182-8927
Markus StempelViral Immune Modulation Research Group, Helmholtz Centre for Infection Research (HZI), Braunschweig, Germany.ORCID http://orcid.org/0000-0002-9240-3987
Kendra A BusseyViral Immune Modulation Research Group, Helmholtz Centre for Infection Research (HZI), Braunschweig, Germany.ORCID http://orcid.org/0000-0002-9357-1456
Elisa ReimerViral Immune Modulation Research Group, Helmholtz Centre for Infection Research (HZI), Braunschweig, Germany.
Jürgen PodlechInstitute for Virology and Research Center for Immunotherapy (FZI), University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.ORCID http://orcid.org/0000-0002-7062-9088
Stefan LienenklausInstitute for Laboratory Animal Science, Hannover Medical School, Hannover, Germany.
Matthias J ReddehaseInstitute for Virology and Research Center for Immunotherapy (FZI), University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
Stipan JonjićCenter for Proteomics, Faculty of Medicine, University of Rijeka, Rijeka, Croatia.
Melanie M BrinkmannViral Immune Modulation Research Group, Helmholtz Centre for Infection Research (HZI), Braunschweig, Germany.ORCID http://orcid.org/0000-0001-5431-6527
Helmholtz Centre for Infection Research · DEJohannes Gutenberg University Mainz · DEUniversity of Rijeka · HRMedizinische Hochschule Hannover · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The type I interferon (IFN) response is imperative for the establishment of the early antiviral immune response. Here we report the identification of the first type I IFN antagonist encoded by murine cytomegalovirus (MCMV) that shuts down signaling following pattern recognition receptor (PRR) sensing. Screening of an MCMV open reading frame (ORF) library identified M35 as a novel and strong negative modulator of IFNβ promoter induction following activation of both RNA and DNA cytoplasmic PRR. Additionally, M35 inhibits the proinflammatory cytokine response downstream of Toll-like receptors (TLR). Using a series of luciferase-based reporters with specific transcription factor binding sites, we determined that M35 targets NF-κB-, but not IRF-mediated, transcription. Expression of M35 upon retroviral transduction of immortalized bone marrow-derived macrophages (iBMDM) led to reduced IFNβ transcription and secretion upon activation of stimulator of IFN genes (STING)-dependent signaling. On the other hand, M35 does not antagonize interferon-stimulated gene (ISG) 56 promoter induction or ISG transcription upon exogenous stimulation of the type I IFN receptor (IFNAR). M35 is present in the viral particle and, upon MCMV infection of fibroblasts, is immediately shuttled to the nucleus where it exerts its immunomodulatory effects. Deletion of M35 from the MCMV genome and hence from the viral particle resulted in elevated type I IFN transcription and secretion in vitro and in vivo. In the absence of M35, lower viral titers are observed during acute infection of the host, and productive infection in the salivary glands was not detected. In conclusion, the M35 protein is released by MCMV immediately upon infection in order to deftly inhibit the antiviral type I IFN response by targeting NF-κB-mediated transcription. The identification of this novel viral protein reinforces the importance of timely countermeasures in the complex relationship between virus and host.

Indexed as

Signal TransductionAnimalsCytomegalovirus InfectionsInterferon-betaInterferon Type IMacrophagesMiceMuromegalovirusNF-kappa BProtein BindingReceptors, Pattern RecognitionToll-Like ReceptorsViral ProteinsInterferon-betaInterferon Type INF-kappa BReceptors, Pattern RecognitionToll-Like ReceptorsViral Proteins

Identifiers

PMID28542326
PMCPMC5444856
OpenAlexW2619508899

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.